| Literature DB >> 25218028 |
So-Jung Kim1, Ga-Hee Ha2, Jae-Ho Bae2, Ga Rim Kim2, Cheol-Hun Son3, You-Soo Park3, Kwangmo Yang3, Sae-Ock Oh4, Sun-Hee Kim5, Chi-Dug Kang6.
Abstract
In the present study, we investigated whether celecoxib could induce the expression of NKG2D ligands in clonogenic colon cancer cells, and increase their susceptibility to NK cell-mediated cell death. Celecoxib and its non-coxib analog, 2,5-dimethyl celecoxib, induced ULBP-1 and DR5 in both COX-2 negative HCT-15 cells and COX-2 positive HT-29 cells. Celecoxib increased their susceptibility to NK92 cells in both DELFIA assay and soft agar colony forming assay. The inducibility of ULBP-1 and DR5 by celecoxib was not different between CD44- and CD44+ HCT-15 cells, and CD133- and CD133+ HT-29 cells. Celecoxib increased the susceptibility of highly clonogenic CD44+ HCT-15 and CD133+ HT-29 cells to NK92 cells, at least comparable to less clonogenic CD44- HCT-15 and CD133- HT-29 cells, respectively. In addition, celecoxib induced CHOP, and thapsigargin, an inducer of ER (endoplasmic reticulum) stress, induced DR5 but not ULBP1 in HCT-15. Taken together, these findings suggest that celecoxib induces the expression of ULBP-1 as well as DR5 in clonogenic colon cancer cells via COX-2 and ER stress-independent pathways, and increases their susceptibility to NK cells.Entities:
Keywords: Cancer stem cells; Celecoxib; Colon cancer; NKG2D ligands
Mesh:
Substances:
Year: 2014 PMID: 25218028 DOI: 10.1016/j.yexcr.2014.09.008
Source DB: PubMed Journal: Exp Cell Res ISSN: 0014-4827 Impact factor: 3.905